Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer gains rights to EML4-ALK patents from CST, Astellas

Executive Summary

Cell Signaling Technology Inc. (CST; research tools for identifying mechanisms underlying cell function and disease) and Astellas Pharma Inc. have licensed Pfizer Inc. nonexclusive global rights to their patent estates covering echinoderm microtubule-associated protein-like 4 (EML4) anaplastic lymphoma kinase (ALK).
Deal Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing

Related Companies

Advertisement
UsernamePublicRestriction

Register